



Vita Life Sciences Limited

ACN 003 190 421

ABN 35 003 190 421

Corporate Office

1/102 Bath Road,
Kirrawee NSW 2232

P.O. Box 3143
Kirrawee NSW 2232

T/Free: 1800 852 222

T: 02 9545 2633

F: 02 9545 1311

vitalifesciences.com

11 May 2022

Company Announcements Office
Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Dear Sir/ Madam,

ANNUAL GENERAL MEETING-ADDRESS & PRESENTATION

The Vita Life Sciences Ltd addresses to the 2022 AGM by the Chairman and the Managing Director with related presentation is attached.

This announcement has been authorised for released by the Board.

Yours faithfully,

A handwritten signature in black ink, appearing to read 'Chin L Khoo'.

Chin L Khoo
Company Secretary
Tel: 02 9545 2633
enquiries@vitalifesciences.com.au

Vita Life Sciences Limited – 2022 Annual General Meeting

Chairman's Script

Vita Life Sciences Limited – 2022 Annual General Meeting

Chairman's Script - 11 May 2022

Welcome

Good afternoon ladies and gentlemen. I am Greg Ralph, a Director of Vita Life Sciences Limited and the Chairman for the Annual General Meeting today.

Welcome to the VLS 2022 Annual General Meeting. Henry Townsing, VLS's Chairman extends his apologies for being unable to chair today's meeting as he is unwell and unable to travel from Melbourne to be with us in person. Henry is however attending online.

We are conducting this AGM in a hybrid manner, whereby shareholders can either attend in person or via teleconference. If you experience any difficulties with your connection to the AGM, you may contact our share registry, Automic on 1300 288 664.

It is now just after noon and, there being a quorum present, I declare the meeting has been properly constituted and open for business.

Introduction

I have pleasure in introducing my fellow Directors who are in attendance:

- Andrew O'Keefe, our Managing Director; and
- Shane Teoh, a non-executive Director.

Also present is our Company Secretary and CFO, Mr Chin Khoo and the Company's external auditor representative, Mr Nicholas Bennett. Mr Joseph Santangelo the audit partner is also present online. There will be opportunity for shareholders to ask questions to the Auditor as well as the Board on financial and business matters later in the meeting.

OUTLINE OF MEETING

Our business begins with the Managing Director's presentation and, then the formal items of business as set out in the Notice of Meeting.

As this meeting is being conducted as a hybrid meeting, I would like to welcome those shareholders that are joining us online and ask that you please submit any questions or comments via the Q&A function which can be found at the bottom of your screen. When you submit a question or comment, please start by typing which resolution it relates to so that it can be addressed at the appropriate time.

Questions which relate to the general business of the Company will be collected and addressed after the close of the formal business of the meeting.

I will now hand over the meeting to Andrew O'Keefe, our Managing Director who will be presenting a report on the Company's business.

Andrew O'Keefe

Thank you, Greg for the introduction.

AGENDA 1 MANAGING DIRECTORS PRESENTATION

Refer to Managing Directors Presentation

[Upon Completion of MD's Presentation Andrew, hands the conduct of the meeting to the Chairman]

AGENDA 2 RESOLUTIONS

Thank you, Andrew for that presentation. We shall now commence the formal business of the meeting.

The Notice of Annual General Meeting was mailed to all registered members on or about 11 April 2022 and is to be taken as read. Voting on all resolutions will be conducted by poll.

For the purposes of the poll, I appoint the representative of Automic, the Company's share registry, who has examined and prepared summaries of the proxy forms received, to act as Returning Officer and to conduct the poll.

Shareholders in attendance online who have **already submitted their votes by proxy** should note that your votes will already be counted towards the poll. You do not need to lodge another vote unless you wish to change your votes.

Shareholders in attendance online who have **not submitted their votes by proxy** and wish to vote on the resolutions being put to the meeting today can do so by following the instructions provided in the Notice of Meeting. On your screen, there are instructions for how to log into the online voting portal.

Please note that the online voting portal is now open and will remain open until the poll is declared closed. Your votes must be submitted prior to the poll being closed for them to count. You should only submit your votes once by clicking “NEXT”, AFTER the voting is concluded at the end of all the six resolutions. We will allocate sufficient time at the end of the final resolution for shareholders to submit their votes.

The proxies have been inspected and all those validly lodged have been accepted.

Proxies have been received representing up to 38,179,643 Shares or around 68% of the issued capital of the Company.

All undirected proxies or open votes that have nominated the Chairman of the Meeting as their proxy, will be cast in favour of each resolution in the Notice of the AGM.

We will now proceed to the resolutions set out in the Notice of AGM.

Financial Statements and Reports of Directors and Auditors

I turn now to the first item of business on the agenda, the consideration of the Financial Statements and Reports. The financial report and the reports of the directors and the auditors are now laid before the meeting. There will be no vote on this item as it is a discussion item only.

The Company’s auditor for the 2021 financial year, **Mr Joseph Santangelo and Mr Nicholas Bennett** of Nexia Sydney Audit Pty Ltd is present to take questions relevant to

the conduct of the audit and the preparation and content of the independent auditor's report.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

Is there any discussion or questions on the 2021 Financial Reports?

Are there any questions relevant to the conduct of the audit and the preparation and content of the auditor's report to be put to the auditor?

[PAUSE AND TAKE QUESTIONS]

If there are no further question, I declare that the reports have been received and considered at this meeting.

Remuneration Report

In accordance with the Notice of Meeting, I now move onto item 2, Resolution 1 which is as follows:

*To consider and, if thought fit, to pass, with or without amendment, **Resolution 1**, Adoption of the Remuneration Report for the Financial year ended 31 December 2021, as an **ordinary resolution**.*

I note that while the vote on this item is advisory only and does not bind the Company nor its directors, the Board and Remuneration Committee takes into consideration the feedback we receive from shareholders.

An explanation of the item is to be found on page 9 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Members of the Company's key management personnel who were named in the FY2021 remuneration report and their closely related parties are reminded that they may not vote on this resolution.

Shareholders may now vote on Resolution 1. May I again remind shareholders not to click on "NEXT", until all five the resolutions have been voted on.

If there are no further questions I will move to the next resolution.

Resolution 2: Re-election of Director – Mr Shane Teoh

I put forward Resolution 2:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 2**, as an **ordinary resolution**.

"That Shane Teoh, a director retiring by rotation in accordance with rule 5.1 of the Constitution, being eligible and having consented to act, be re-elected as a director of the Company."

An explanation of Resolution 2 and information on Mr Teoh is found on page 10 of the Notice of the Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 2. May I again remind shareholders not to click on "NEXT" until all the five resolutions have been voted on.

If there are no further questions I shall move to the next resolution.

Resolution 3: Re-election of Director- Mr Henry Townsing

I put forward Resolution 3:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 3**, as an **ordinary resolution**.

“That Henry Townsing, a director retiring by rotation in accordance with rule 5.1 of the Constitution, being eligible and having consented to act, be re-elected as a director of the Company.”

An explanation of Resolution 3 and information on Mr Townsing is found from page 10 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 3. I again remind shareholders, not to click on “NEXT” until all the five resolutions have been voted on.

I shall move to the next resolution.

Resolution 4: Share-Buy Back

I put forward Resolution 4:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 4**, as an **ordinary resolution**.

“That pursuant to and in accordance with section 257C of the Corporations Act 2001 (C’wlth), as amended, Rules 7.29 and 7.33 of the Listing Rules of ASX Limited, and for all other purposes, the shareholders approve, with effect from when the Directors make the relevant announcement to the ASX, the on-market buy-back of up to 15% of the fully paid ordinary

shares in the Company expiring on whichever is the earlier of the anniversary of the passage of this resolution or the 2023 Annual General Meeting and otherwise on the terms and conditions set out in the Explanatory Statement accompanying the 2022 Annual General Notice of Meeting at which this resolution is to be put.”

An explanation of Resolution 4 and information the share buy-back, is found from page 11 of the Notice of Meeting.

The number of valid proxy votes that have been received on this motion are shown on the screen.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A.

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 4. I again remind shareholders not to click on “NEXT” until all the five resolutions have been voted on.

If there are no further questions I shall move to the next resolution.

Resolution 5: Long Term Incentive Plan: Grant of Limited Recourse Loan to the Managing Director to Purchase Ordinary Shares

I put forward Resolution 5:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 5**, as an **ordinary resolution**.

"That pursuant to ASX Listing Rule 10.14 and in accordance with Vita Life Sciences Limited's "Long Term Incentive Plan" (Plan), tabled by the Chairman and initialled by him for purposes of identification, approval is given for the Directors to issue 500,000 new ordinary, fully paid shares in the Company and make a limited recourse loan to Mr Andrew O'Keefe, acting in his capacity as the Managing Director of the Company, for a sum of \$945,000 (Loan), which

will be used to fund the purchase of shares, on the terms summarised in the Explanatory Statement accompanying the Notice of 2022 Annual General Meeting"

An explanation of Resolution 5 is to be found from page 13 of the Explanatory Statement in the Notice of AGM.

The number of valid proxy votes that have been received on this motion are shown on the screen.

All Directors and any management personnel of the Company who are eligible to participate in the Plan and their closely related parties are reminded that they may not vote on this resolution.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 5 and click on "NEXT" to submit all their votes.

Resolution 6: Long Term Incentive Plan: Grant of Limited Recourse Loan to a Director to Purchase Ordinary Shares

I put forward Resolution 6:

To consider and, if thought fit, to pass, with or without amendment, **Resolution 5**, as an **ordinary resolution**.

"That pursuant to ASX Listing Rules 10.14 and in accordance with Vita Life Sciences Limited's "Long Term Incentive Plan" (Plan), tabled by the Chairman and initialled by him for purposes of identification, approval is given for the Directors to issue 300,000 new ordinary, fully paid shares in the Company and make a limited recourse loan to Mr Henry Townsing, acting in his capacity as a Director of the Company, for a sum of \$567,000 (Loan), which will

be used to fund the purchase of shares, on the terms summarised in the Explanatory Statement accompanying the Notice of 2022 Annual General Meeting"

An explanation of Resolution 6 is to be found from page 16 of the Explanatory Statement in the Notice of AGM.

The number of valid proxy votes that have been received on this motion are shown on the screen.

All Directors and any management personnel of the Company who are eligible to participate in the Plan and their closely related parties are reminded that they may not vote on this resolution.

If you have any questions or wish to discuss this resolution, please submit your questions via the Q&A

[PAUSE AND TAKE QUESTIONS]

Shareholders may now vote on Resolution 6 and click on "NEXT" to submit all their votes.

Ladies and gentlemen, that concludes our discussion on the formal items of business. As mentioned earlier, we are conducting a Poll for all resolutions. I note the poll is already opened. The number of valid proxy votes that have been received for all resolutions are shown on the screen.

Can all shareholders voting online please ensure that you have submitted your votes – I will allow another minute before declaring the poll is closed. If you have any questions in relation to the submission of online votes, please send them through the Q&A function now.

I will now pause for about one minute to allow shareholders time to finalise and, submit their votes online.

Pause for a minute

There being no further questions I now declare voting is closed. The staff of Automic will now process the poll and the results will be announced to the ASX once they are available.

AGENDA 3 OTHER BUSINESS & QUESTION TIME

Is there any other business that can lawfully be brought forward?

[PAUSE TO CONSIDER]

If there are none, I now invite shareholders to forward any questions for management or the auditor via the Q&A.

[PAUSE AND TAKE QUESTIONS]

MEETING CLOSE

There being no further questions or matters for discussion, I'd like to thank all shareholders for their attendance and will now end the today's meeting. I declare the meeting closed.

Vita Life Sciences Limited – 2022 Annual General Meeting

Managing Director's Script

Vita Life Sciences Limited – 2022 Annual General Meeting

Address by the Managing Director – 11 May 2022

Opening remarks

Thank you, Greg.

Good afternoon and a warm welcome to all shareholders, VLS Board of directors and to the Vita Life Sciences Executive Team. My name is Andrew O’Keefe, Managing Director of Vita Life Sciences.

Thank you for joining the Company’s Annual General Meeting. My address will provide shareholders with an update into the Groups FY 2021 achievements, along with an update on progress against the Groups strategy.

Thank you to our people

I would like to take this opportunity to recognise all the wonderful staff across the entire organisation. The Covid-19 pandemic continued to test us like many companies in our sector. I’m extremely proud of the team’s commitment to the cause and I’m privileged to work alongside each one of you.

Over the past year, the organisation remained extremely focused and vigilant in deploying a very deliberate strategy to capitalise on the increasing demand for complementary medicine. Through the dedication and support of our staff and customers, the Group has delivered a record performance and record dividend for shareholders.

Meeting consumer demand

The Group maintained distribution coverage across several markets. The core includes Australia, Malaysia, and Singapore. The remaining countries being China, Vietnam with representations in Thailand and Indonesia, to round out our market presence.

- 3 major consumer brands - Herbs of Gold, VitaHealth & VitaScience
- 750 registered products across all markets

One of the challenges the business confronted was to ensure we had the capability to meet the increased demand for our products, whilst navigating our way through significant global supply chain disruption.

Product supply pressures posed a serious risk to the business. A decision was made in the early stages of the pandemic to increase stock levels across key product categories to mitigate stock outages. Accordingly, the Group was able to capitalise on the demand for our products and leverage stronger relationship with both our retail partners and consumers.

The consumer demand for immunity products continued throughout FY21. The consumers were researching and seeking trusted products with high strength formulations to help support their health needs. Whilst, the immunity category drove the consumer demand, sub segments also experienced strong growth across the VHMS category.

Strong financial performance

The business implemented a strong strategic plan that increased the momentum delivered over the past few years. The VLS Group delivered record sales of \$57.1M, up 22.9% on the prior corresponding period (PCP) and a pre-tax profit of \$11.2M, compared to the PCP of \$8.1M.

This performance reflects the strategy set for the business to build on our base, whilst generating revenues from new channels in our core markets. The strategic partnership in China also generated solid revenue growth through cross-border E-commerce channel (CBEC) activities and is reflected in the Australian sales sector. Our China strategy provides a simplified route to market, which reduces channel conflict and ensures greater control measures across the supply chain.

Our balance sheet remains strong with equity of \$30.4M, net cash of \$15.9M without any borrowings.

Based on sustained margins and profit performance of the Group, a total dividend payment 5.75 cents per share was declared for FY21 an increase of 1.5 cents from FY2020.

Geographical contributions

In terms of geographical market contributions, the FY21 revenue mix has changed slightly from FY20; Australia is the single largest market with an increase from 45% to 53%, which includes exports into China. The increase was driven mainly by export contributions, higher consumer demand and channel expansion within the Australian Pharmacy channel.

It's important to recognise the Asia Pacific region of our business, which represents 47% of the group's revenue. The region remains a significant strategic pillar for VLS in terms of risk diversity and continued brand expansion.

Strategic Priorities

The Company has demonstrated a history of prudent financial disciplines. Our business has emerged from 2021 in even greater shape, maintaining its strong balance sheet and even stronger cash position. The Company will continue to invest across four key strategic pillars and leverage market potential including:

- Brand building: driving consumer and retailer engagement
- Education & Innovation: implementation of high-quality education programs

- Talent Wellbeing: recruitment of additional management personal to support growth expectations
- Operational leverage: ERP integration to increase supply chain and customer interface efficiencies.

The business has progressed well against our strategic pillars over the past 12 months. We have implemented several new initiatives that supports both our key pillars and growth agenda.

Some of the key initiatives include:

- Strong penetration across the Pharmacy Channel in Australia with over 1000 Pharmacies ranging Herbs of Gold products.
- Recruitment of a national training team to support the Australian domestic business.
- Implementation of the new ERP system in Q4 21.
- Increased branding across all major E- commerce across the China market.
- Launched 30 new products across our respective markets.
- Redeployed a new business model in Thailand and Indonesia.

Over the next 12 months, the company will continue to build on the 4 strategic pillars. The company has indicated an appetite to continue investing back into the business and in turn, positively impact the Group's financial performance.

Outlook

The Group continues to be very well positioned to leverage market opportunities across the region. The plans and vision for the business remain strong and robust to deliver future growth.

The company will be providing first half guidance in early June.

In closing, I would like to again thank all the hard-working staff of Vita Life Sciences. I would also like to thank all shareholders and customers and look forward to your ongoing support.

Thank you for your attention. I will now hand the meeting back to Greg.

Andrew O'Keefe
Managing Director

Vita Life Sciences Limited – 2022 Annual General Meeting

Presentation Materials

Vita Life Sciences AGM - Registration and Voting

1. Log in or register at:
<https://investor.automic.com.au/#/home>

2. Click view and register your attendance for the meeting

3. Record your vote. Once you confirm it is lodged and final



The screenshot shows the Automic investor portal interface. On the left, there's a promotional banner for Automic's services. On the right, there's a login and registration section. It includes a link for existing users to sign in, input fields for username and password, a 'log in' button, and a 'register' button. Below the login fields, there's a link for users who can't log in.

The screenshot shows the 'Meetings' section of the Automic portal. It displays a timeline of meetings. A meeting for 'Sample Corporation LTD Annual General Meeting' is scheduled for 12 Aug 2020 at 3:30 PM. The meeting is marked as 'voting ends' and 'Register'. Below the meeting details, it states 'No more upcoming meetings' and provides a 'back to portfolio' link.

The screenshot shows the 'Voting' section of the Automic portal. It displays a progress bar with four steps: Registration, Poll, Review, and Complete. The current step is 'Review - Step 3 of 4'. The review section includes a 'Confirmation' section with a 'Remuneration Report' and a 'Re-Election of Mr Robert Smith as Director'. Each item has 'for', 'against', and 'abstain' buttons. Below the review section, there's a 'Declaration' section with a 'PLEASE NOTE' and a 'confirm' button. At the bottom, there are 'prev' and 'confirm' buttons.

To contact support:
Call 1300 816 159 or open live chat from the Investor Portal

Annual General Meeting

11 May 2022



AGM Agenda

1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTIONS & ANSWERS



Henry Townsing

Chairman

Mr Townsing brings over 30 years' experience in corporate finance and private equity.

He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22nd December 2011.

Mr Townsing was appointed as the Chairman of the Company effective 28th May 2021 and is also the chairman of the Company's Board Nomination and Remuneration Committees.

AGM Agenda


1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTIONS & ANSWERS



Andrew O'Keefe

Managing Director

Mr O'Keefe was appointed Managing Director on 1st January 2017. Mr O'Keefe has over 20 years' experience within the Australian pharmaceutical and healthcare industry. During his career Mr O'Keefe has held senior leadership positions in publicly listed companies and was the CEO of Australia's largest health food distributor and retailer. Andrew O'Keefe was appointed to the position of Chief Executive Officer – Herbs of Gold Australia in October 2014.





Thank you

Meeting Consumer Demand

Distribution - Across several markets; Australia, Malaysia, Singapore, China, Vietnam, Thailand, and Indonesia

Brands – Herbs of Gold, VitaHealth & VitaScience brands

Products – 750 registered products across all markets

Strong consumer demand – The Group meets increased demand in a disrupted global supply chain environment

Supply Chain Pressure – Increased stock holdings across all major categories mitigates stock outages



Strong Financial Performance



Record Sales
\$57.1m, up 23%



Pre-Tax Profit
\$11.2m, up 38%



Balance sheet equity
\$30.4m, net cash \$15.9m
(without any borrowings)




Dividend payment
5.75 cents/share,
up 35%

Geographical Performance


Australia is the single largest market with an increase of 45% to 53% in market share.

2021 revenue by geography



Strategic priorities

Our pillars



Key initiatives to support our pillars



Outlook

- The Group continues to be very well positioned to leverage market opportunities across the region.
- The plans and vision for the business are strong and robust to drive future growth.
- First half guidance will be provided early June.



AGM Agenda

1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTIONS & ANSWERS

Ordinary Resolutions

1. Remuneration Report
2. Re-election of Director – Shane Teoh
3. Re-election of Director- Henry Townsing
4. Share buy back
5. Long Term Incentive Plan Shares-Managing Director
6. Long Term Incentive Plan Shares-Director

Proxy-Resolution 1

| | RESOLUTIONS | IN FAVOUR | AGAINST | PROXY'S DISCRETION | EXCLUDED |
|----|-------------------------------------|------------|---------|-----------------------|------------|
| 1) | Adoption of the Remuneration Report | 25,502,045 | 43,100 | 0 | 11,220,054 |

Proxy-Resolution 2

| | RESOLUTIONS | IN FAVOUR | AGAINST | PROXY'S DISCRETION | EXCLUDED |
|----|---|------------|---------|-----------------------|----------|
| 2) | Re-election of Director (Shane Teoh) | 38,153,410 | 21,915 | 0 | 0 |

Proxy-Resolution 3

| | RESOLUTIONS | IN FAVOUR | AGAINST | PROXY'S DISCRETION | EXCLUDED |
|----|---|------------|---------|-----------------------|----------|
| 3) | Re-election of Director (Henry Townsing) | 37,429,676 | 66,915 | 0 | 0 |

Proxy-Resolution 4

| | RESOLUTIONS | IN FAVOUR | AGAINST | PROXY'S DISCRETION | EXCLUDED |
|----|----------------|------------|---------|-----------------------|----------|
| 4) | Share buy-back | 38,127,790 | 50,344 | 0 | 0 |

Proxy-Resolution 5

| | RESOLUTIONS | IN FAVOUR | AGAINST | PROXY'S DISCRETION | EXCLUDED |
|----|--|------------|---------|-----------------------|------------|
| 5) | Long Term Investment Plan Shares- Managing Director | 25,426,542 | 164,047 | 0 | 11,077,054 |

Proxy-Resolution 6

| | RESOLUTIONS | IN FAVOUR | AGAINST | PROXY'S DISCRETION | EXCLUDED |
|----|---|------------|---------|--------------------|------------|
| 6) | Long Term Investment Plan Shares-Director | 25,350,385 | 240,204 | 0 | 10,394,446 |

Proxy

| | RESOLUTIONS | IN FAVOUR | AGAINST | PROXY'S DISCRETION | EXCLUDED |
|----|--|------------|---------|--------------------|------------|
| 1) | Adoption of the Remuneration Report | 25,502,045 | 43,100 | 0 | 11,220,054 |
| 2) | Re-election of Director (Shane Teoh) | 38,153,410 | 21,915 | 0 | 0 |
| 3) | Re-election of Director (Henry Townsing) | 37,429,676 | 66,915 | 0 | 0 |
| 4) | Share buy-back | 38,127,790 | 50,344 | 0 | 0 |
| 5) | Long Term Investment Plan Shares- Managing Director | 25,426,542 | 164,047 | 0 | 11,077,054 |
| 6) | Long Term Investment Plan Shares- Director | 25,350,385 | 240,204 | 0 | 10,394,446 |

AGM Agenda

1. CHAIRMAN'S WELCOME ADDRESS
2. MANAGING DIRECTOR'S REVIEW
3. ORDINARY RESOLUTIONS
4. QUESTIONS & ANSWERS

Disclaimer

This document has been prepared by Vita Life Sciences Limited (**Vita Life Sciences**) and comprises written material/slides for a presentation concerning Vita Life Sciences.

The presentation is for information purposes only and does not constitute nor form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements that have not been independently verified. These forward looking statements speak only as at the date of this presentation. These statements are based on certain assumptions, expectations, estimates, projections and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such statements.

No representation, warranty or assurance (express or implied) is given or made by Vita Life Sciences that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Vita Life Sciences and its respective directors, officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Vita Life Sciences disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Vita Life Sciences since the date of this presentation.